Artificial Intelligence Decision-Making in Multidisciplinary Tumor Boards for Head and Neck Cancer: A Systematic Review.

Authors

Karl Bouchard-Locat, Vincent Raby, Apostolos Christopoulos, Houda Bahig, Russell Schwartz, Paul Tabet, Mathieu Belzile, Tareck Ayad

Published in

Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale. Volume 55. Pages 19160216261451777. Epub Oct 13, 2026.

Abstract

Artificial intelligence (AI) is increasingly integrated into clinical decision-making, including applications in pathology, radiomics, and multidisciplinary tumor boards (MDT) for head and neck (ENT) cancer. However, the current scope and performance of AI tools within MDT settings remain unclear.
To systematically evaluate the existing literature on the use and performance of AI models in MDT decision-making for ENT cancer.
Systematic review.
Studies assessing AI applications in MDT for head and neck (ENT) cancer.
A systematic search of Cochrane, Embase, Medline, PubMed, and Scopus was conducted from database inception to March 4, 2025. Studies were included without language or date restrictions. The review was conducted in accordance with PRISMA guidelines.
AI performance across 4 key domains: therapy option selection, clinical recommendations, explanation capabilities, and summarization abilities.
Of 791 records screened, 37 underwent full-text review and 7 met inclusion criteria. Six AI models were evaluated, with ChatGPT-4 featured in 71% of included studies. Across assessed domains, ChatGPT-4 demonstrated superior performance compared to other models, particularly in therapy selection, recommendation quality, and explanatory capacity.
The current evidence base regarding AI integration in MDT decision-making for ENT cancer remains limited and heterogeneous. Although ChatGPT-4 shows promising performance across multiple domains, concerns regarding clinical accuracy, consistency, and transparency persist. Further research is required to optimize AI reliability and validate its clinical utility.
Clarifying the capabilities and limitations of AI within MDT settings is essential to ensure safe integration into oncologic decision-making and to support future development of reliable, transparent AI-assisted clinical tools.

PMID:
42865335
Bibliographic data and abstract were imported from PubMed on 13 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.